Blocking TIM-3 with anti-TIM-3 antibodies at the early stage of sepsis reduced its severity, alleviated lung and liver injuries, decreased inflammatory responses, and prevented lymphocyte apopsosis (64). This evidence concerns the gene HAVCR2 and Sepsis.